Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.
Publication
, Conference
Lonardi, S; Andre, T; Wong, KYM; Morse, M; McDermott, R; Hill, A; Hendlisz, A; Lenz, H; Leach, J; Moss, RA; Cao, ZA; Ledeine, J; Kopetz, S; Overman, M
Published in: Ann Oncol
October 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2017
Volume
28 Suppl 6
Start / End Page
vi3
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lonardi, S., Andre, T., Wong, K. Y. M., Morse, M., McDermott, R., Hill, A., … Overman, M. (2017). Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study. In Ann Oncol (Vol. 28 Suppl 6, p. vi3). England. https://doi.org/10.1093/annonc/mdx422.001
Lonardi, S., T. Andre, K. Y. M. Wong, M. Morse, R. McDermott, A. Hill, A. Hendlisz, et al. “Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.” In Ann Oncol, 28 Suppl 6:vi3, 2017. https://doi.org/10.1093/annonc/mdx422.001.
Lonardi S, Andre T, Wong KYM, Morse M, McDermott R, Hill A, et al. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study. In: Ann Oncol. 2017. p. vi3.
Lonardi, S., et al. “Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study.” Ann Oncol, vol. 28 Suppl 6, 2017, p. vi3. Pubmed, doi:10.1093/annonc/mdx422.001.
Lonardi S, Andre T, Wong KYM, Morse M, McDermott R, Hill A, Hendlisz A, Lenz H, Leach J, Moss RA, Cao ZA, Ledeine J, Kopetz S, Overman M. Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 Study. Ann Oncol. 2017. p. vi3.
Published In
Ann Oncol
DOI
EISSN
1569-8041
Publication Date
October 2017
Volume
28 Suppl 6
Start / End Page
vi3
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis